Genesys International to set ₹139.3 cr rights issue terms

Committee meeting scheduled for July 31, 2026

Genesys International Corporation Limited has scheduled a meeting of its Rights Issue Committee for July 31, 2026. The meeting is meant to finalise the key commercial terms of the company’s proposed equity rights issue. The company has indicated that the committee will decide the issue price, the rights entitlement ratio, and the record date. These parameters will determine both the valuation at which new shares are offered and which shareholders are eligible to participate. The rights issue involves fully paid-up equity shares with a face value of ₹5 each.

The July 31 meeting is a procedural milestone after the board laid down the broad approval earlier. Until the committee confirms the commercial terms, the detailed impact on shareholders remains pending. Once the committee concludes, the company is expected to make further disclosures with the finalised terms.

What the committee is expected to decide

The company has outlined that the Rights Issue Committee will focus on defining the mechanics of the offer. The agenda items are centred on the parameters that matter most to existing shareholders. These include the price per share at which the rights will be offered, and the entitlement ratio which sets how many new shares an investor can subscribe to based on current holdings. The record date will determine the eligibility cut-off.

The committee is also expected to close any other modalities linked to process and administration. These decisions typically shape the subscription experience, including timelines and operational details. The company has stated that disclosures will follow after the committee’s decisions.

Board approval came on June 26, 2026

The rights issue was approved at a board meeting held on June 26, 2026. At that meeting, the board approved raising funds through a rights issue of equity shares to eligible shareholders. The maximum amount proposed to be raised is ₹139.3 crore (also stated as ₹13,930 lakh). The equity shares proposed to be issued under the rights issue carry a face value of ₹5 each.

While the board approved the fund-raising framework and size cap, it did not set the specific commercial parameters. Instead, the board authorised the determination of details such as the issue price, entitlement ratio, record date, timing of the issue and payment terms through the board and or a duly constituted committee. The Rights Issue Committee was constituted for the purposes of issue, offer and allotment of equity shares and for other matters connected with the rights issue.

Regulatory framework and disclosures referenced

Genesys International has referenced compliance requirements in its disclosures around the process. The rights issue is stated to be subject to regulatory and statutory approvals, including those under the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The company has also cited SEBI listing disclosure obligations in the context of board decisions.

Separately, the July 31 committee meeting is positioned as part of the disclosure-driven process, including compliance with SEBI Regulation 42 disclosure norms in relation to record date related communication. The company’s next updates are expected to clarify the final terms once the committee takes its decisions.

Authorised share capital increased to support the issuance

Alongside the rights issue process, the board approved an increase in authorised share capital. The authorised share capital has been increased from ₹27.25 crore to ₹45.00 crore. The disclosure also states that this adds 3.55 crore equity shares (also presented as 355.00 lakh shares).

An authorised capital increase does not by itself issue new shares, but it expands the legal headroom for issuing equity. For shareholders tracking capital actions, this step often accompanies planned equity issuance so that the company has sufficient authorised capacity to complete the proposed offer.

Promoter share pledge disclosed in July

The article text also notes a promoter pledge event. Sajid Malik, described as Promoter of Genesys International Corporation Ltd, pledged 920,728 shares (2.20%) to HDFC Bank on July 1, 2026, to secure working capital facilities. The disclosure states that this raised his total encumbered holding to 5.04%.

In addition, the provided promoter encumbrance table lists Sajid Siraj Malik with 1,186,046 shares pledged or otherwise encumbered. The text also states that the promoter group and persons acting in concert did not create any new share encumbrances during FY2025-26, based on the promoter declaration referenced.

Key facts investors can track now

With the board approval already in place, the immediate next trigger is the July 31 committee decision. For existing shareholders, the record date will determine eligibility to receive rights entitlements. The issue price and entitlement ratio together will define the cost and the size of participation available relative to current holdings.

The company has indicated that further filings will follow once the committee finalises the terms. Until then, the precise subscription economics and the detailed impact on holdings cannot be inferred from the information currently available. Investors monitoring the rights issue will typically watch for the final terms and the subsequent subscription window communications.

Market impact: why the pending terms matter

The key market-sensitive elements here are the issue price and entitlement ratio, because these determine how the rights issue is structured for existing holders. The record date is equally important because it sets the eligibility cut-off and guides investor positioning in the lead-up to the corporate action. With only the maximum fund-raise amount currently known at ₹139.3 crore, the number of shares to be issued and the potential dilution cannot be determined from the provided information.

The authorised capital increase provides structural support for the proposed issuance, and signals that the company is preparing for equity issuance within the approved ceiling. Meanwhile, promoter encumbrance disclosures are often tracked by investors for balance-sheet and funding context, and the article provides specific pledged share data and the stated percentage of encumbered holding.

Analysis: what to watch after July 31

The July 31 committee meeting is the inflection point that should convert a board-approved plan into a clearer offer framework for shareholders. Once the issue price, entitlement ratio and record date are announced, shareholders will be able to quantify participation requirements and compare the rights issue pricing with prevailing market levels at that time. It will also enable investors to understand the overall mechanics of the offering and how eligibility will be determined.

The company has also indicated that the rights issue is subject to regulatory and statutory approvals, which means the final execution will depend on completion of the necessary process under applicable laws and SEBI regulations. The next disclosures after the committee meeting should therefore be read alongside the formal regulatory steps communicated by the company.

Conclusion

Genesys International has set July 31, 2026 as the date for its Rights Issue Committee to finalise the issue price, entitlement ratio and record date for its proposed ₹139.3 crore rights issue of ₹5 face value equity shares. The plan follows board approval on June 26, 2026 and comes alongside an increase in authorised share capital from ₹27.25 crore to ₹45.00 crore. The next actionable update for shareholders is the company’s post-meeting disclosure, expected to publish the final terms and eligibility cut-offs for the upcoming offering.